PI-103

PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHJNE05KM7:TR?= M3jadFI1NzR6L{eyJIg> NIrBNZBqdmS3Y3XzJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2aX;uJI9vKE6EIHPlcIwh\3Kxd4To M2D0RlI3OjJ2Nkix
SH-SY5Y MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\RdlAuQCEQvF2= MUKyOE81QC95MjDo M3HB[Ilv\HWlZYOgeIlu\S1iYX7kJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXSrb36gc44hVkJiY3XscEBoem:5dHi= MVWyOlIzPDZ6MR?=
SH-SY5Y  Mn[0RZBweHSxc3nzJGF{e2G7 NXL6OFhnOSEQvF2= NXSzO3FXOC53LUK0JIg> MorYd4Vve2m2aYrld{Bv\XW{b3LsZZN1d22jIHPlcIx{KHSxIHTvfI9zfWKrY3nuMYlv\HWlZXSgZZBweHSxc3nz M4fNSlI3OjJ2Nkix
G 35 SC MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUewMlA2NTJyIN88US=> NFzn[VQzPC95MjDo NFHsTGtFVVOR NUjLfG06cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= M1XjWVI3OTJzMkWx
G 38 SC NX3YcXZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS2N|hxOC5yNT2yNEDPxE1? NYHhTpJlOjRxN{KgbC=> MXXEUXNQ M1TuTYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? M{\uR|I3OTJzMkWx
G 40 SC NH;NbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnVNE4xPS1{MDFOwG0> M3XhblI1Nzd{IHi= NI\I[JpFVVOR M4DMT4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? MmHVNlYyOjF{NUG=
G 35 DC MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfiVHUxNjB3LUKwJO69VQ>? MX6yOE84OiCq M13QWGROW09? MVnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NF[xZ|gzPjF{MUK1NS=>
G 38 DC M4flSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXuNE4xPS1{MDFOwG0> NX:wTYRjOjRxN{KgbC=> MVTEUXNQ M{WySolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? MYKyOlEzOTJ3MR?=
G 40 DC NF\XPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSwMlA2NTJyIN88US=> M{PCblI1Nzd{IHi= NYGxNFVCTE2VTx?= MkL2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MY[yOlEzOTJ3MR?=
RD MX7BdI9xfG:|aYOgRZN{[Xl? NWn5R2FyOS9zLkWvNkDPxE1? MmnYO|IhcA>? NFzGc5hqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? NH[xOFIzPTd2OUO3PC=>
TE381.T MVPBdI9xfG:|aYOgRZN{[Xl? M2PxNlEwOS53L{Kg{txO NXnx[GlRPzJiaB?= MX\pcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> MlvWNlU4PDl|N{i=
RMS13 MmPiRZBweHSxc3nzJGF{e2G7 M1y2RlEwOS53L{Kg{txO M1rwdVczKGh? M{DGVYlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy MoTYNlU4PDl|N{i=
RH30  Ml7ZRZBweHSxc3nzJGF{e2G7 Ml7lNU8yNjVxMjFOwG0> M4nkS|czKGh? M2\ORYlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy NIq2dJMzPTd2OUO3PC=>
VJ MoO3RZBweHSxc3nzJGF{e2G7 MlKxNU8yNjVxMjFOwG0> M1ToUVczKGh? NVPVR2cycW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? M4PHSFI2PzR7M{e4
HS578T MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUi2NmZkOC1|IN88US=> NWOzZYFWPzJiaB?= MXLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NHOzXpIzPTd{MUSxPS=>
BT549 NFvxTYhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUWwMVMh|ryP Mni5O|IhcA>? NFyzW5RqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MmTnNlU4OjF2MUm=
MDA-MB-231 NGHFWoxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXKwMVMh|ryP MXu3NkBp NFz1ZnhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NWS5VoE1OjV5MkG0NVk>
MDA-MB-468 NEPMSmtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEDvOYYxNTNizszN MmPqO|IhcA>? MWPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M2XW[FI2PzJzNEG5
MDA-MB-436 MorMR4VtdCCYaXHibYxqfHliQYPzZZk> MUOwMVMh|ryP MX[3NkBp MYTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NFz6Z4szPTd{MUSxPS=>
SUM149PT MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVywMVMh|ryP MUW3NkBp NVuxNnhvcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mm\mNlU4OjF2MUm=
MDA-MB-468 NXPRW4ZPTnWwY4Tpc44hSXO|YYm= MYiwMlAyNTFyIN88US=> NGLUfFUzPCCq Ml7w[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wy|IH;mJO6zNVS{Q2CxMEBkNU27YzDhcoQh[3mlbHnuJGUheHKxdHXpcpPDqA>? NIfaR3gzPTd{MUSxPS=>
MDA-MB-231 MX;GeY5kfGmxbjDBd5NigQ>? M{jjflAvODFvMUCg{txO MYiyOEBp MUPkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh MXeyOVczOTRzOR?=
HS578T NHnVNoNHfW6ldHnvckBCe3OjeR?= NGGyPHcxNjBzLUGwJO69VQ>? NWTKcJRXOjRiaB?= M4PHVIRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? NVjURm5yOjV5MkG0NVk>
SW872 MVfGeY5kfGmxbjDBd5NigQ>? M2Cyc|AvODFvMD61JO69VQ>? M{jWSFI1KGh? NH36N4dz\WS3Y3XzJGFMXCCyaH;zdIhwenmuYYTpc44hMHCDS2SpJIFv\CB2RVLQNUBxcG:|cHjvdplt[XSrb36gLJA1TUKSMTmgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> NXXuV5o4OjR4OUW2N|I>
SW982 MmfTSpVv[3Srb36gRZN{[Xl? MXuwMlAyNTBwNTFOwG0> NXHYeWg{OjRiaB?= NFLDWFNz\WS3Y3XzJGFMXCCyaH;zdIhwenmuYYTpc44hMHCDS2SpJIFv\CB2RVLQNUBxcG:|cHjvdplt[XSrb36gLJA1TUKSMTmgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> NFzLVXYzPDZ7NU[zNi=>
SW872 NYD2eHU6SXCxcITvd4l{KEG|c3H5 MYmwMlAyNTBwNTFOwG0> M3GxcFQ5KGh? NHPMcFFqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NVnydm9uOjR4OUW2N|I>
SW982 MV3BdI9xfG:|aYOgRZN{[Xl? NV;HWol7OC5yMT2wMlUh|ryP NYjpUpNrPDhiaB?= MY\pcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 M{nzWFI1Pjl3NkOy
AGS HG NVryV|RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknyTWM2OD1yLk[4JOKyKDBwMEOxJO69VQ>? MnXtNlQ2QTd2N{i=
AGS LG M4fhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi2TXNKSzVyPUCuNFUhyrFiMD6wNFEh|ryP NFLaXokzPDV7N{S3PC=>
HGC27 HG NHG0NodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i3WmlEPTB;MD6zPEDDuSByLkCyNkDPxE1? MXiyOFU6PzR5OB?=
HGC27 LG M2XWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEKgxtEhOC5yMESg{txO Mkm5NlQ2QTd2N{i=
MKN45 HG NV76ZmozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[zbmlEPTB;MT6wNUDDuSByLkC1NUDPxE1? NGDJc4ozPDV7N{S3PC=>
MKN45 LG Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK0TWM2OD1yLki3JOKyKDBwMEOwJO69VQ>? NEjFcnIzPDV7N{S3PC=>
NUGC4 HG M3PmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e4fGlEPTB;MUSuNEDDuSB|LkmxN{DPxE1? MmnuNlQ2QTd2N{i=
NUGC4 LG MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\zTWM2OD1zND6wJOKyKDVwM{KxJO69VQ>? Mom0NlQ2QTd2N{i=
A549 NH\2S4FHfW6ldHnvckBCe3OjeR?= Mlv4NE4zPS9yLkWvNUDPxE1? NEXDfmkzPCCq NXeyfoU4cW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|bHnnbJRtgQ>? M13ERVI1OzVzNEK1
H460 MXXGeY5kfGmxbjDBd5NigQ>? MViwMlI2NzBwNT:xJO69VQ>? NFjsOFIzPCCq MXPpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNtcWeqdHz5 NGHE[JczPDN3MUSyOS=>
H661 NInJWm9HfW6ldHnvckBCe3OjeR?= MUOwMlI2NzBwNT:xJO69VQ>? NUe2Tod5OjRiaB?= Moj5bY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 NEnOUY4zPDN3MUSyOS=>
SAS MlO3SpVv[3Srb36gRZN{[Xl? MWKwMlI2NzBwNT:xJO69VQ>? NFfo[5EzPCCq MmGxbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 NXO5fJhIOjR|NUG0NlU>
UT5 NYLafmZNTnWwY4Tpc44hSXO|YYm= M4[3V|AvOjVxMD61M|Eh|ryP M{HlblI1KGh? NXHTT4M4cW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 NXjxcZRROjR|NUG0NlU>
FaDu M4HPUGZ2dmO2aX;uJGF{e2G7 M{LUVVAvOjVxMD61M|Eh|ryP NEjJfGUzPCCq NXLOTm1icW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 NFv2[pUzPDN3MUSyOS=>
RD MYLBdI9xfG:|aYOgRZN{[Xl? MUixM|EvPS9{IN88US=> MXe3NkBp M1XxVmROW09? MnHzbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> NYXxWGtHOjN4OES5NlU>
TE671 MnrDRZBweHSxc3nzJGF{e2G7 NIPIXJIyNzFwNT:yJO69VQ>? NWDmUpVDPzJiaB?= MlX2SG1UVw>? MVvpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 M3\VTVI{Pjh2OUK1
RH30  M1XHfmFxd3C2b4Ppd{BCe3OjeR?= M1fIeVEwOS53L{Kg{txO MV[3NkBp M4jNTGROW09? NILNeJZqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 NXTqdm1OOjN4OES5NlU>
RMS13 NVfBOWMySXCxcITvd4l{KEG|c3H5 M1TGblEwOS53L{Kg{txO MmrrO|IhcA>? NWXaXXRYTE2VTx?= NYDN[ZhFcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? NX7OdZdqOjN4OES5NlU>
SUM149PT M4PGXGNmdGxiVnnhZoltcXS7IFHzd4F6 M{fCblAvOyEQvF2= MWO3NkBp NVyxWFE6\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K| NFHGT2MzOzZyMUC3OC=>
MDA-MB-468 Ml;nR4VtdCCYaXHibYxqfHliQYPzZZk> NHnEXpAxNjNizszN NETReWY4OiCq NUnobpNu\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K| M{f4ZVI{PjBzMEe0
MDA-MB-231 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXTodoVpOC5|IN88US=> MljCO|IhcA>? Mn7H[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ MXyyN|YxOTB5NB?=
SY5Y NEDVe4JHfW6ldHnvckBCe3OjeR?= MWmxMlUwOi53L{Wg{txO MYGyOEBp Ml:zbY5lfWOnczDHNeKh[2WubD3jfYNt\SCjcoLld5Qh[W6mIHHwc5B1d3Orcx?= MYWyN|M4QDN2MR?=
SKNBE(2c) NXixco5rTnWwY4Tpc44hSXO|YYm= MUWxMlUwOi53L{Wg{txO NVLuUHY{OjRiaB?= M2O2bIlv\HWlZYOgS|HDqGOnbHytZ5lkdGViYYLy[ZN1KGGwZDDhdI9xfG:|aYO= M3XKWlI{Ozd6M{Sx
RD M3\pbGFxd3C2b4Ppd{BCe3OjeR?= M37kTlMhyrWP Mo\6NVIhcA>? MXfEUXNQ M1rlN5NmdnOrdHn6[ZMhWkRiY3XscJMhfG9iRF;YMYlv\HWlZXSgZZBweHSxc3nz NETxfYQzOzNyMEiwPS=>
TP5014 MUPBdI9xfG:|aYOgRZN{[Xl? M4T5N|MhyrWP NGDHXlkyOiCq NEH3UIVFVVOR NX[5TGxze2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> NG\LTlczOzNyMEiwPS=>
HT1080 MlHsRZBweHSxc3nzJGF{e2G7 M3S4NlMhyrWP M4X3ZVEzKGh? MVjEUXNQ NX:0[lVye2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> MkftNlM{ODB6MEm=
A549 NHvLXWFHfW6ldHnvckBCe3OjeR?= MXWwMVMvOyEQvF2= Mn3wO|IhcA>? NHXXXIFqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? NF33UYIzOzJ3OUW5NS=>
HCC827 NET4SXZHfW6ldHnvckBCe3OjeR?= NF7oNJgxNTNwMzFOwG0> Moj3O|IhcA>? NFjiTY5qdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? M3HZNVI{OjV7NUmx
H3122 MVnGeY5kfGmxbjDBd5NigQ>? MnXXNE0{NjNizszN MYW3NkBp MUTpcoR2[2W|IHPvcZBt\XSnIHTve45z\We3bHH0bY9vKG:oIIDBT3Q> NHnkS4QzOzJ3OUW5NS=>
TALL-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWx5qCK|ryP Mm\CO{Bl M4Kye4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MV:yN|A{QDJ5Mx?=
HPB-ALL NYnU[GQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKyNgKBkc7:TR?= NIjnZ5o4KGR? NUXVTmQ2\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 Mmi5NlMxOzh{N{O=
DND41 M3zmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnHbo1rOeLCid88US=> MlfBO{Bl MnjO[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MoXmNlMxOzh{N{O=
SUP-T1 NH\2bGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrBNgKBkc7:TR?= NU[zRlJSPyCm MVjk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M4PTW|I{ODN6Mkez
PEER MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[yUZRiOeLCid88US=> MVm3JIQ> NXvKZ2RL\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MX:yN|A{QDJ5Mx?=
ALL-SIL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XXPVHjiIoQvF2= MnTTO{Bl NYLmNXBZ\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NUjWWnVTOjNyM{iyO|M>
KE37 M1y4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG1NgKBkc7:TR?= NES2[5M4KGR? M1vjfYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NFLKO2IzOzB|OEK3Ny=>
Karpas-45 NXjNOZQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Ww[VHjiIoQvF2= NXLmTGF2PyCm NXG0VYxL\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 M4WwOlI{ODN6Mkez
RPMI-8402 MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1foR|HjiIoQvF2= NVToeYp[PyCm NUniWo1W\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MWGyN|A{QDJ5Mx?=
Jurkat MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTkc|c2OeLCid88US=> NF:4ZW04KGR? NGLBWGJl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NWT6cIFUOjNyM{iyO|M>
MOLT-4 M1XQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTtNgKBkc7:TR?= MknwO{Bl NHTDNpZl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NF\RdZozOzB|OEK3Ny=>
PF-382 NWnHZpBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r5NFHjiIoQvF2= MV23JIQ> MVXk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MWiyN|A{QDJ5Mx?=
CCRF-CEM MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[x5qCK|ryP M4Xke|ch\A>? Mknq[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MXyyN|A{QDJ5Mx?=
LOUCY NFXScYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO0bG0y6oDLzszN MnniO{Bl NYjObG5P\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NHnaT|czOzB|OEK3Ny=>
MOLT-16 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPkNgKBkc7:TR?= M2f5S|ch\A>? NV3MOItW\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MlnCNlMxOzh{N{O=
MM1S NX7NcWQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqwMVIh|ryP M4HnfVI1KGh? M2TrSmlEPTB;MD61JO69VQ>? MWCyNlgzQTJ|NB?=
NCI-H929 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjhWnQxNTJizszN MYqyOEBp M17z[GlEPTB;MD6yOUDPxE1? M2Tad|IzQDJ7MkO0
KMS12-BM  NYXmNopiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\3NE0zKM7:TR?= MWiyOEBp MX7JR|Ux97zgMjFOwG0> MYSyNlgzQTJ|NB?=
MDA-MB-436 NFW3dmRHfW6ldHnvckBCe3OjeR?= MXOxJO69VQ>? M4XneVI1KGh? NULXW4p6emWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> NULsNmhiOjJ2OEi1PVA>
SUM149PT M{H4WWZ2dmO2aX;uJGF{e2G7 MlO5NUDPxE1? M2\hbFI1KGh? MnzUdoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MnXrNlI1QDh3OUC=
SUM1315MO2 MWPGeY5kfGmxbjDBd5NigQ>? NWj6ZVUzOSEQvF2= M2iyOVI1KGh? MWjy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW NH7hO5EzOjR6OEW5NC=>
HCC1937 Mof6SpVv[3Srb36gRZN{[Xl? MVmxJO69VQ>? NVG0bHo{OjRiaB?= Ml\RdoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= NXLTTnc{OjJ2OEi1PVA>
HCC827 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq5d|gxNTNizszN MkjmO|IhcA>? MkmyTWM2OD1yLkOg{txO Ml7uNlEzOjB2N{S=
PC-9  M4HoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfvRoE6OC1|IN88US=> MljNO|IhcA>? M2rsTGlEPTB;MD64JO69VQ>? NGjEVWEzOTJ{MES3OC=>
LN229 M1;x[mZ2dmO2aX;uJGF{e2G7 NEiz[JgyKM7:TR?= M4DhZ|Q5KGh? MWXpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v MUOyNVA3Ojl7Mx?=
U87 M4HHSmZ2dmO2aX;uJGF{e2G7 M2XvTVEh|ryP NFyzW4g1QCCq NVPQZnkycW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= NXLmemNZOjFyNkK5PVM>
U373 M13mOGZ2dmO2aX;uJGF{e2G7 Mkj0NUDPxE1? Moq5OFghcA>? M4TIZ4lv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? MYqyNVA3Ojl7Mx?=
SF767 M1X3[mZ2dmO2aX;uJGF{e2G7 NFrVdFQyKM7:TR?= NX;qb3JWPDhiaB?= NVW1NGN[cW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= Mkm3NlExPjJ7OUO=
Mel-Juso MnHtR4VtdCCYaXHibYxqfHliQYPzZZk> NVXzPXIxOC5yMfMAl|Ex6oDLzszN NIrycXc4OiCq NXS5WoZmcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M3nHW|IyODR6N{i1
518A2  M4\VPWNmdGxiVnnhZoltcXS7IFHzd4F6 MnfBNE4xOeLCk{Gw5qCK|ryP M1XwWVczKGh? NVLrSmhEcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M3XqTVIyODR6N{i1
Mel-Juso  M{\rVWZ2dmO2aX;uJGF{e2G7 NUTlcmFHOC5yMEJihLMy6oDLzszN MmfwNlQhcA>? MkHRd5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= NWGyNIFZOjFyNEi3PFU>
518A2 NXnMZ5dOTnWwY4Tpc44hSXO|YYm= M3HzelAvODBz4pETNgKBkc7:TR?= MkjUNlQhcA>? MoP5d5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= NFHkSoszOTB2OEe4OS=>
PC3  NYrmZ5NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjvNlRp NIXjSW1IUTVywrC9JFExOCCwTR?= Mnz4NlA2PTFyNkG=
U87MG M{fLWGZ2dmO2aX;uJGF{e2G7 MW[wMlEuOSEQvF2= M4PtclI16oDLaNMg NYGyfJVJTE2VTx?= NULtVJVCcW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= NYnKUGxnOTl4M{O2PFM>
U138MG MXzGeY5kfGmxbjDBd5NigQ>? Mn7qNE4yNTFizszN NWrvXIVMOjUkgJnoxsA> MWHEUXNQ M3XNRolvcGmkaYTzJHBKO0tvbXXkbYF1\WRic3nncoFtcW6p NX;OTVV6OTl4M{O2PFM>
U118MG NVG4V2U6TnWwY4Tpc44hSXO|YYm= M1rOelAvOS1zIN88US=> M1W1fFI16oDLaNMg M4HDOmROW09? NW\nOmQzcW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= MnSzNVk3OzN4OEO=
U87MG NWrlN3k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X0UWlEPTB;MD6xOEDPxE1? Ml7tNVk2QDR{Mke=
IGROV-1 M4fkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\pdWlEPTB;MD6wOkDPxE1? M3\5VFE6PTh2MkK3
DETROIT562 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHDTWM2OD1yLkGzJO69VQ>? MVSxPVU5PDJ{Nx?=
PC3  NITVZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXTbWZnUUN3ME2wMlExKM7:TR?= NWrhNZZMOTl3OESyNlc>
SKOV-3 NI[3OGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XZTmlEPTB;MD6xNkDPxE1? M1ziUlE6PTh2MkK3
HUVEC NIDYR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjpZ|BKSzVyPUCuNFgh|ryP M4fyO|E6PTh2MkK3
UCH-1  MoTFSpVv[3Srb36gRZN{[Xl? NFHGPWYxNTVizszN NFnUcmNqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIHLveIghSUuWIHHu[EBuXE:UIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3LTdFE6PTJ6NESx
UCH-1  MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;yWlAvODFvMUCg{txO NY\sNYxJPiCm M{KwTolvcGmkaYTzJJBzd2yrZnXyZZRqd25iZH;z[UBl\XCnbnTlcpRtgQ>? NUfHZ3pDOTl3Mki0OFE>
UCH-1  NYrke4VpSXCxcITvd4l{KEG|c3H5 NYjJeXVvOC5zLUGwJO69VQ>? NFvEbXUzPCCq NY\uSZFMTE2VTx?= MoLFbY5lfWOnczDhdI9xfG:|aYO= NH3PPXEyQTV{OES0NS=>

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ